



Public Health
England

Protecting and improving the nation's health

Clinical Headline Indicators

Purpose

The Clinical Headline Indicators (CHI) will measure the quality of care and patient outcomes that are of the highest clinical importance and impact. They will be published at trust and network level and are aimed at commissioners and providers of cancer care in England.

They will evolve over time as the quality and range of data improve.

Background

Clinical Headline Indicators

Core cancer dataset upon which to build indicators of activity, performance and outcomes of cancer care in England.

Pilot using Breast and Lung (based on service profiles)

Set of Generic Indicators (all tumour sites)

Set of site specific indicators (defined by SSCRG)

ICD10 groupings (based on commissioner / analyst requirements)

CHI – Home page

Contact details	
Programme Manager	Kath Yates 07769 282 924
Project Data Officer	Carl Francis 020 7654 8331 or x48331

Queries

For queries regarding the content of CHI – either ring Kath / Carl or email quoting CHI to

enquiries@ncin.org.uk

Site Specific Analytical leads for v1 release

Brain CNS	Sarah Miller
Breast	.John Broganio

Introduction

[Clinical Headline Indicators](#) ▾

[Data Library](#)

Clinical Headline Indicators

Introduction

Clinical Headline Indicators or CHI produces a range of indicators for the purposes of informing the commissioning and provision of cancer services and driving up standards of care/ activity / performance to improve outcomes for patients of cancer care in England. V1 includes a Generic set of indicators (relevant for most tumour sites) and site specific for Lung and Breast. CHI is based on the Service Profiles (that have currently been available within the Cancer Commissioning Toolkit) giving a snapshot of data based on data received via the cancer registration service.

Background

CHI is derived with expert clinical input using a range of data, initially, though not exclusively, from the COSD dataset. All indicators are discussed and agreed with site specific clinical reference groups. There is a project board to oversee the delivery of data and ensure the indicators meet necessary commissioning requirements.

The National Cancer Registration Service (NCRS) team is working closely with National Cancer Intelligence Network (NCIN) to produce this tool / data. Supporting information can be found in the data library.

CHI – Home page

The screenshot shows the CHI home page interface. On the left, a navigation menu is open under the heading "Clinical Headline Indicators". The menu items are: Home, Data Library, Brain and CNS, Breast, Gynaecology, Head and Neck, Lower GI, Lung, Sarcoma, and Urology. To the right of the menu, there are labels for "University H", "Indicators", "Year:", "Trust:", "our Site:", and "Month". In the center, a vertical stack of buttons includes: Size, Demographics, Case Mix, Process, Diagnostics, Treatment, and Outcome. On the right, a "Diagnostics" section is highlighted, containing a sub-section titled "4.5a With a valid stage recorded" and a description: "4.5a Number and proportion of patients with a valid stage by Trust".

CHI – Indicator descriptions



National Cancer Intelligence Network Clinical Headline Indicators

Metadata for Breast site-specific indicators in CHI

Size

4.1a Diagnosed per year

Number of new patients treated by a Trust

Category	Site Specific (4.9)
CHI Indicator title : <i>Equivalent Number/Title in Service Profile:</i>	That are recorded as screen detected <i>BR7: Newly diagnosed cases (from #2) referred via the screening service</i>
4.9a Description	Cases referred via breast cancer screening were identified using the NHSBSP and ABS breast screening audit database. This contains patient level records of all women referred by the screening service and subsequently diagnosed with breast cancer (both invasive and in-situ).
Diagnosis which are covered (ICD10)	Primary diagnosis codes are C50 and D05
Rationale & Evidence	TBC
Specification	<p>Numerator – The number of cases diagnosed with primary breast cancer who were referred via the screening service</p> <p>Denominator – The total number of cases treated for breast cancer in the Trust</p> <p>Rate or Proportion – The proportion of cases diagnosed with primary breast cancer who were referred via the screening service, defined as the number of persons diagnosed with primary breast cancer who were referred via the screening service divided by the number of cases diagnosed with primary breast cancer.</p> <p>Exclusions –</p>
Display on CHI by	Number, percentage
Interpretation	The proportion of screen detected cases can inform the understanding of subsequent treatment within different Trusts.
National Standard/Target	Tbc

CHI – SCN summary

	Total	Q1	Q2	Q3	Q4
+ Cheshire And Mersey	2089	488	475	551	557
+ East Midlands	3820	917	908	953	954
+ East Of England	5510	1255	1479	1435	1341
+ Greater Manchester, Lancashire & South Cumbria	4588	1072	1154	1158	1184
+ London Cancer	2875	683	709	734	749
+ London Cancer Alliance	3893	909	990	1034	980
+ North East, North Cumbria, And North Yorks	2993	709	744	729	811
+ South East Coast	5249	1211	1285	1448	1305
+ South West	5171	1277	1234	1400	1280
+ Thames Valley	1882	437	485	512	448
+ Wessex	2886	670	653	651	692
+ West Midlands	5189	1285	1312	1335	1277
+ Yorkshire And The Humber	5375	1273	1338	1418	1348

CHI – tumour selection

- Size
- Demographics
- Case Mix
- Process
- Diagnostics
- Treatment
- Outcome
- Lung
- Breast

Clinical Headline Indicators

4.1a Diagnosed per year - Breast tumours 2013

Year:	Clear	2013
SCN:	Clear	All
Measure:	Clear	4.1a Diagnosed per year
Tumour Site:	Clear	Breast
Report View	Clear	Quarterly

Apply

Export ▾

	Total	Q1	Q2	Q3	Q4
+ Cheshire And Mersey	2069	486	475	551	557
+ East Midlands	3820	917	996	953	954

CHI – Generic Measures

Generic Measures

	Total		Q1		Q2		Q3		Q4	
Size										
4.1a Diagnosed per year	162		30		44		45		43	
Demographics										
4.2a Aged 70+	61	38%	10	33%	13	30%	17	38%	21	49%
4.2b Male patients	1	1%	1	3%	0	0%	0	0%	0	0%
4.2c With recorded ethnicity	152	94%	29	97%	40	91%	43	96%	40	93%
4.2d – Which is not White-British	6	4%	2	7%	0	0%	3	7%	1	2%
4.2e With an index of multiple deprivation score of 5 (most deprived)	68	42%	12	40%	19	43%	15	33%	22	51%
Casemix										
4.3a With a performance status of 0-1 recorded	79	49%	19	63%	23	52%	21	47%	16	37%
Process										
4.4a Discussed at MDT	154	95%	30	100%	40	91%	42	93%	42	96%
4.4b Having CNS contact recorded (codes Y1/Y2)	145	90%	29	97%	38	86%	41	91%	37	86%
4.4c Presenting via GP referral (referral source 03)	126	78%	23	77%	36	82%	35	78%	32	74%
4.4d Presenting via emergency referral (referral source 01, 04, 10)	1	1%	0	0%	0	0%	0	0%	1	2%
Diagnostic										
4.5a With a valid stage recorded	134	83%	24	80%	38	86%	39	87%	33	77%
4.5b With early stage (stage 1 or 2) recorded	98	60%	17	57%	25	57%	31	69%	25	58%
4.5c With a histological confirmed diagnosis (basic 5, 6 or 7)	161	99%	30	100%	44	100%	45	100%	42	96%
Treatments										
4.6a Receiving surgery	83	51%	19	63%	23	52%	16	36%	25	58%
4.6b Receiving chemotherapy	1	1%	0	0%	1	2%	0	0%	0	0%
4.6c Receiving radiotherapy	0	0%	0	0%	0	0%	0	0%	0	0%
4.6d With active treatment	142	88%	27	90%	35	80%	40	89%	40	93%
4.6e Entered in a clinical trial	0	0%	0	0%	0	0%	0	0%	0	0%
Outcomes										
4.7a Died within a year of diagnosis	9	6%	1	3%	3	7%	2	4%	3	7%

CHI – Generic Measures

Size
4.1a Diagnosed per year
Demographics
4.2a Aged 70+
4.2b Male patients
4.2c With recorded ethnicity
4.2d – Which is not White-British
4.2e With an index of multiple deprivation score of 5 (most deprived)
Casemix
4.3a With a performance status of 0-1 recorded

Process
4.4a Discussed at MDT
4.4b Having CNS contact recorded (codes Y1/Y2)
4.4c Presenting via GP referral (referral source 03)
4.4d Presenting via emergency referral (referral source 01, 04, 10)
Diagnostics
4.5a With a valid stage recorded
4.5b With early stage (stage 1 or 2) recorded
4.5c With a histological confirmed diagnosis (basis 5, 6 or 7)
Treatments
4.6a Receiving surgery
4.6b Receiving chemotherapy
4.6c Receiving radiotherapy
4.6d With active treatment
4.6e Entered in a clinical trial
Outcome
4.7a Died within a year of diagnosis

CHI – breast Site Specific Measures

Site-Specific Measures

	Total		Q1		Q2		Q3		Q4	
Breast										
4.9a That are recorded as screen detected	0	0%	0	0%	0	0%	0	0%	0	0%
4.9b Managed at this trust with invasive cancer (C50)	152	94%	27	90%	42	95%	43	96%	40	93%
4.9c Managed at this trust with non-invasive cancer (D05)	10	6%	3	10%	2	5%	2	4%	3	7%
4.9d With a nationally registered Nottingham Prognostic Index	104	88%	19	70%	23	55%	33	77%	29	73%
4.9e – With nationally registered NPI in excellent or good prognostic groups	25	18%	4	15%	2	5%	9	21%	10	25%
4.9f Major surgeries in invasive breast cancer	119	78%	21	78%	33	79%	34	79%	31	78%
4.9g – Receiving mastectomy (invasive only)	54	45%	11	52%	18	55%	13	38%	12	39%
4.9h – Receiving sentinel lymph node biopsy (invasive only)	75	63%	13	62%	21	64%	18	53%	23	74%
Surgery										
4.9i Surgery Count	140		28		38		41		35	
4.9j – Surgeries which are day case or one overnight stay	63	45%	18	69%	12	32%	12	29%	21	60%
4.9k – Median length stay (days) for elective surgical admissions)	4.25	-%	3		6		3.5		5	
4.9l – Mean length stay (days) for elective surgical admissions)	1.96	-%	3.14		6.5		3.58		10.27	